Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions
Identifieur interne : 000240 ( France/Analysis ); précédent : 000239; suivant : 000241Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions
Auteurs : Murer [France] ; Gustavo Dziewczapolski [Argentine] ; Liliana B. Menalled [Argentine] ; M. Carmen García [Argentine] ; Yves Agid [France] ; Oscar Gershanik [Argentine] ; Rita Raisman-Vozari [France]Source :
- Annals of Neurology [ 0364-5134 ] ; 1998-05.
Abstract
Orally administered levodopa remains the most effective symptomatic treatment for Parkinson's disease (PD). The introduction of levodopa therapy is often delayed, however, because of the fear that it might be toxic for the remaining dopaminergic neurons and, thus, accelerate the deterioration of patients. However, in vivo evidence of levodopa toxicity is scarce. We have evaluated the effects of a 6‐month oral levodoapa treatment on several dopaminergic markers, in rats with moderate or severe 6‐hydroxydopamine‐induced lesions of mesencephalic dopamine neurons and sham‐lesioned animals. Counts of tyrosine hydroxylase (TH)‐immunoreactive neurons in the substantia nigra and ventral tegmental area showed no significant difference between levodopa‐treated and vehicle‐treated rats. In addition, for rats of the sham‐lesioned and severely lesioned groups, immunoradiolabeling for TH, the dopamine transporter (DAT), and the vesicular monoamine transporter (VMAT2) at the striatal level was not significantly defferent between rats treated with levodopa or vehicle. It was unexpected that quantification of immunoautoradiograms showed a partial recovery of all three dopaminergic markers (TH, DAT, and VMAT2) in the denervated territories of the striatum of moderately lesioned rats receiving levodopa. Furthermore, the density of TH‐positive fibers observed in moderately lesioned rats was higher in those treated chronically with levodopa than in those receiving vehicle. Last, that chronic levodopa administration reversed the up‐regulation of D2 dopamine receptors seen in severely lesioned rats provided evidence that levodopa reached a biologically active concentration at the basal ganglia. Our results demonstrate that a pharmacologically effective 6‐month oral levodopa treatment is not toxic for remaining dopamine neurons in a rat model of PD but instead promotes the recovery of striatal innervation in rats with partial lesions.
Url:
DOI: 10.1002/ana.410430504
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Main, to step Corpus: 001E58
- to stream Main, to step Curation: 001B71
- to stream Main, to step Exploration: 001F18
- to stream France, to step Extraction: 000240
Links to Exploration step
ISTEX:27DC216D2C0D2A1D16C43DED13551629E339E704Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions</title><author><name sortKey="Murer" sort="Murer" uniqKey="Murer" last="Murer">Murer</name></author><author><name sortKey="Dziewczapolski, Gustavo" sort="Dziewczapolski, Gustavo" uniqKey="Dziewczapolski G" first="Gustavo" last="Dziewczapolski">Gustavo Dziewczapolski</name></author><author><name sortKey="Menalled, Liliana B" sort="Menalled, Liliana B" uniqKey="Menalled L" first="Liliana B." last="Menalled">Liliana B. Menalled</name></author><author><name sortKey="Garcia, M Carmen" sort="Garcia, M Carmen" uniqKey="Garcia M" first="M. Carmen" last="García">M. Carmen García</name></author><author><name sortKey="Agid, Yves" sort="Agid, Yves" uniqKey="Agid Y" first="Yves" last="Agid">Yves Agid</name><affiliation><country>France</country><placeName><settlement type="city">Paris</settlement><region type="region" nuts="2">Île-de-France</region></placeName><orgName type="hospital" n="4">Hôpital de la Salpêtrière</orgName></affiliation></author><author><name sortKey="Gershanik, Oscar" sort="Gershanik, Oscar" uniqKey="Gershanik O" first="Oscar" last="Gershanik">Oscar Gershanik</name></author><author><name sortKey="Raisman Ozari, Rita" sort="Raisman Ozari, Rita" uniqKey="Raisman Ozari R" first="Rita" last="Raisman-Vozari">Rita Raisman-Vozari</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:27DC216D2C0D2A1D16C43DED13551629E339E704</idno><date when="1998" year="1998">1998</date><idno type="doi">10.1002/ana.410430504</idno><idno type="url">https://api.istex.fr/document/27DC216D2C0D2A1D16C43DED13551629E339E704/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001E58</idno><idno type="wicri:Area/Main/Curation">001B71</idno><idno type="wicri:Area/Main/Exploration">001F18</idno><idno type="wicri:Area/France/Extraction">000240</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions</title><author><name sortKey="Murer" sort="Murer" uniqKey="Murer" last="Murer">Murer</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>INSERM U289, Hǒpital de la Salpětrière, Paris</wicri:regionArea><placeName><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Dziewczapolski, Gustavo" sort="Dziewczapolski, Gustavo" uniqKey="Dziewczapolski G" first="Gustavo" last="Dziewczapolski">Gustavo Dziewczapolski</name><affiliation wicri:level="1"><country xml:lang="fr">Argentine</country><wicri:regionArea>Instituto de Investigaciones Farmacológicas, CONICET, Buenos Aires</wicri:regionArea><wicri:noRegion>Buenos Aires</wicri:noRegion></affiliation></author><author><name sortKey="Menalled, Liliana B" sort="Menalled, Liliana B" uniqKey="Menalled L" first="Liliana B." last="Menalled">Liliana B. Menalled</name><affiliation wicri:level="1"><country xml:lang="fr">Argentine</country><wicri:regionArea>Instituto de Investigaciones Farmacológicas, CONICET, Buenos Aires</wicri:regionArea><wicri:noRegion>Buenos Aires</wicri:noRegion></affiliation></author><author><name sortKey="Garcia, M Carmen" sort="Garcia, M Carmen" uniqKey="Garcia M" first="M. Carmen" last="García">M. Carmen García</name><affiliation wicri:level="1"><country xml:lang="fr">Argentine</country><wicri:regionArea>Instituto de Investigaciones Farmacológicas, CONICET, Buenos Aires</wicri:regionArea><wicri:noRegion>Buenos Aires</wicri:noRegion></affiliation></author><author><name sortKey="Agid, Yves" sort="Agid, Yves" uniqKey="Agid Y" first="Yves" last="Agid">Yves Agid</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>INSERM U289, Hǒpital de la Salpětrière, Paris</wicri:regionArea><placeName><settlement type="city">Paris</settlement></placeName><placeName><settlement type="city">Paris</settlement><region type="region" nuts="2">Île-de-France</region></placeName><orgName type="hospital" n="4">Hôpital de la Salpêtrière</orgName></affiliation></author><author><name sortKey="Gershanik, Oscar" sort="Gershanik, Oscar" uniqKey="Gershanik O" first="Oscar" last="Gershanik">Oscar Gershanik</name><affiliation wicri:level="1"><country xml:lang="fr">Argentine</country><wicri:regionArea>Instituto de Investigaciones Farmacológicas, CONICET, Buenos Aires</wicri:regionArea><wicri:noRegion>Buenos Aires</wicri:noRegion></affiliation></author><author><name sortKey="Raisman Ozari, Rita" sort="Raisman Ozari, Rita" uniqKey="Raisman Ozari R" first="Rita" last="Raisman-Vozari">Rita Raisman-Vozari</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>INSERM U289, Hǒpital de la Salpětrière, Paris</wicri:regionArea><placeName><settlement type="city">Paris</settlement></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of Neurology</title><title level="j" type="sub">Official Journal of the American Neurological Association and the Child Neurology Society</title><title level="j" type="abbrev">Ann Neurol.</title><idno type="ISSN">0364-5134</idno><idno type="eISSN">1531-8249</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1998-05">1998-05</date><biblScope unit="volume">43</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="561">561</biblScope><biblScope unit="page" to="575">575</biblScope></imprint><idno type="ISSN">0364-5134</idno></series><idno type="istex">27DC216D2C0D2A1D16C43DED13551629E339E704</idno><idno type="DOI">10.1002/ana.410430504</idno><idno type="ArticleID">ANA410430504</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0364-5134</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Orally administered levodopa remains the most effective symptomatic treatment for Parkinson's disease (PD). The introduction of levodopa therapy is often delayed, however, because of the fear that it might be toxic for the remaining dopaminergic neurons and, thus, accelerate the deterioration of patients. However, in vivo evidence of levodopa toxicity is scarce. We have evaluated the effects of a 6‐month oral levodoapa treatment on several dopaminergic markers, in rats with moderate or severe 6‐hydroxydopamine‐induced lesions of mesencephalic dopamine neurons and sham‐lesioned animals. Counts of tyrosine hydroxylase (TH)‐immunoreactive neurons in the substantia nigra and ventral tegmental area showed no significant difference between levodopa‐treated and vehicle‐treated rats. In addition, for rats of the sham‐lesioned and severely lesioned groups, immunoradiolabeling for TH, the dopamine transporter (DAT), and the vesicular monoamine transporter (VMAT2) at the striatal level was not significantly defferent between rats treated with levodopa or vehicle. It was unexpected that quantification of immunoautoradiograms showed a partial recovery of all three dopaminergic markers (TH, DAT, and VMAT2) in the denervated territories of the striatum of moderately lesioned rats receiving levodopa. Furthermore, the density of TH‐positive fibers observed in moderately lesioned rats was higher in those treated chronically with levodopa than in those receiving vehicle. Last, that chronic levodopa administration reversed the up‐regulation of D2 dopamine receptors seen in severely lesioned rats provided evidence that levodopa reached a biologically active concentration at the basal ganglia. Our results demonstrate that a pharmacologically effective 6‐month oral levodopa treatment is not toxic for remaining dopamine neurons in a rat model of PD but instead promotes the recovery of striatal innervation in rats with partial lesions.</div></front></TEI><affiliations><list><country><li>Argentine</li><li>France</li></country><region><li>Île-de-France</li></region><settlement><li>Paris</li></settlement><orgName><li>Hôpital de la Salpêtrière</li></orgName></list><tree><country name="France"><noRegion><name sortKey="Murer" sort="Murer" uniqKey="Murer" last="Murer">Murer</name></noRegion><name sortKey="Agid, Yves" sort="Agid, Yves" uniqKey="Agid Y" first="Yves" last="Agid">Yves Agid</name><name sortKey="Raisman Ozari, Rita" sort="Raisman Ozari, Rita" uniqKey="Raisman Ozari R" first="Rita" last="Raisman-Vozari">Rita Raisman-Vozari</name></country><country name="Argentine"><noRegion><name sortKey="Dziewczapolski, Gustavo" sort="Dziewczapolski, Gustavo" uniqKey="Dziewczapolski G" first="Gustavo" last="Dziewczapolski">Gustavo Dziewczapolski</name></noRegion><name sortKey="Garcia, M Carmen" sort="Garcia, M Carmen" uniqKey="Garcia M" first="M. Carmen" last="García">M. Carmen García</name><name sortKey="Gershanik, Oscar" sort="Gershanik, Oscar" uniqKey="Gershanik O" first="Oscar" last="Gershanik">Oscar Gershanik</name><name sortKey="Menalled, Liliana B" sort="Menalled, Liliana B" uniqKey="Menalled L" first="Liliana B." last="Menalled">Liliana B. Menalled</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/France/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000240 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000240 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= France
|étape= Analysis
|type= RBID
|clé= ISTEX:27DC216D2C0D2A1D16C43DED13551629E339E704
|texte= Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions
}}
| This area was generated with Dilib version V0.6.23. |  |